Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 7;21(1):198.
doi: 10.1186/s12957-023-03077-8.

Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study

Fei Zheng #  1 , Qingju Meng #  2 , Lei Zhang #  3 , Jingli Chen  1 , Liyan Zhao  2 , Zhiguo Zhou  4   5 , Yibing Liu  6   7
Affiliations

Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study

Fei Zheng et al. World J Surg Oncol. .

Abstract

Background: Immunocheckpoint inhibitor(ICI) is a major breakthrough in tumor treatment. It can activate the patient's own immune system and play an anti-tumor role, but not all patients can benefit from it. At present, there is still a lack of effective biomarkers to guide clinical application. The systemic immune inflammation(SII) index reflects the systemic inflammatory state and immune state of patients. Prognostic nutrition index(PNI) can be used to evaluate immune status of patients. Therefore, SII and PNI indexes may have some value in predicting the efficacy and prognosis of immunotherapy, but there is still a lack of relevant research. The purpose of our study was to explore the influence of SII and PNI index on the efficacy and prognosis of immunotherapy.

Methods: A total of 1935 patients treated with ICIs treatment in the Fourth Hospital of Hebei Medical University from November 2016 to October 2021 were retrospectively collected. 435 patients who met the inclusion criteria and did not meet the exclusion criteria. The imaging data, blood results of each patient were collected within 1 week before ICIs treatment. The neutrophil lymphocyte ratio(NLR), platelet lymphocyte ratio(PLR), monocyte lymphocyte ratio(MLR), PNI,systemic inflammatory response index(SIRI),neutrophil-eosinophil ratio(NER) was calculated. The patients were followed up by in-patient, out-patient reexamination and telephone contact, and the efficacy evaluation and survival status were recorded. The deadline of follow-up: January 2021. SPSS-24.0 software was employed for statistical analysis.

Results: Among the 435 patients receiving ICI treatment, 61,236 and 138 patients were evaluated respectively as partial response (PR), stable disease (SD) and progressive disease (PD). The overall response rate(ORR) and disease control rate (DCR) of this cohort were 14.0% and 68.3%, respectively. Median progression-free survival (mPFS) is 4.0 months, The overall survival (mOS) of this cohort is 6.8 months. Multivariate analysis showed that SIRI(Hazard Ratio, HR = 1.304, P = 0.014), PNI (HR = 0.771, P = 0.019), prealbumin (PAB) (HR = 0.596, P = 0.001), and PNI(HR = 0.657, P = 0.008) were independent risk factors for PFS and OS, respectively.

Conclusions: Patients with high SIRI value and low PNI value before ICI treatment have shorter PFS. Patients with higher PNI value have better prognosis. Therefore, hematological indicators may become predictors of immunotherapy.

Keywords: Advanced tumor; Curative effect; Hematological index; Immune checkpoint inhibitor; Prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
PFS and OS. PFS, progression-free survival; OS, overall survival
Fig. 2
Fig. 2
Kaplan–Meier curve of PFS of patients with different AMC, ALB, PNI, and SIRI. PFS, progression-free survival; AMC, absolute monocyte count; ALB, albumin; PNI, prognostic nutritional index; SIRI, systemic inflammatory response index
Fig. 3
Fig. 3
Kaplan–Meier curve of OS of patients with different PAB, ALB, PNI. PFS, progression-free survival; OS, overall survival; PAB, Prealbumin; ALB, Albumin; PNI, prognostic nutritional index
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dai X, Gao Y, Wei W. Post-translational regulations of PD-L1 and PD-1: mechanisms and opportunities for combined immunotherapy. Semin Cancer Biol. 2022;85:246–252. doi: 10.1016/j.semcancer.2021.04.002. - DOI - PMC - PubMed
    1. Xi X, Yang MX, Wang XY, Shen DJ. Predictive value of prognostic nutritional index on infection after radical gastrectomy: a retrospective study. J Gastrointest Oncol. 2022;13(2):569–580. doi: 10.21037/jgo-22-192. - DOI - PMC - PubMed
    1. He Q, Du S, Wang X, Liu J, Xu X, Liu W, Zhang J, Jiang K. Development and validation of a nomogram based on neutrophil-to-lymphocyte ratio and fibrinogen-to-lymphocyte ratio for predicting recurrence of colorectal adenoma. J Gastrointest Oncol. 2022;13(5):2269–2281. doi: 10.21037/jgo-22-410. - DOI - PMC - PubMed
    1. Prelaj A, Rebuzzi SE, Pizzutilo P, et al. EPSILoN: a prognostic score using clinical and blood biomarkers in advanced non-small-cell lung cancer treated with immunotherapy. Clin Lung Cancer. 2020;21(4):365–377.e5. doi: 10.1016/j.cllc.2019.11.017. - DOI - PubMed
    1. Feng L, Xu R, Lin L, Liao X. Effect of the systemic immune-inflammation index on postoperative complications and the long-term prognosis of patients with colorectal cancer: a retrospective cohort study. J Gastrointest Oncol. 2022;13(5):2333–2339. doi: 10.21037/jgo-22-716. - DOI - PMC - PubMed

Substances